{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T01:24:47Z","timestamp":1752283487260,"version":"3.40.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.antiviral.2014.06.005","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T11:23:07Z","timestamp":1403263387000},"page":"7-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner"],"prefix":"10.1016","volume":"109","author":[{"given":"Amedeo","family":"De Nicol\u00f2","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Boglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Ciancio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Cusato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Strona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6880-2753","authenticated-orcid":false,"given":"Chiara Simona","family":"Cardellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Mohamed Abdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cariti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Troshina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Paolo","family":"Caviglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonina","family":"Smedile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Rizzetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1321-4126","authenticated-orcid":false,"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.06.005_b0005","doi-asserted-by":"crossref","unstructured":"Asselah, T., Pasmant, E., Lyoumi, S., 2010. Unraveling the genetic predisposition of ribavirin-induced anaemia. J Hepatol.","DOI":"10.1016\/j.jhep.2010.06.007"},{"key":"10.1016\/j.antiviral.2014.06.005_b0010","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/jvh.12170","article-title":"Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir","volume":"21","author":"Boglione","year":"2014","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.antiviral.2014.06.005_b0015","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1590-8658(12)60122-4","article-title":"F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy","volume":"44","author":"Caviglia","year":"2012","journal-title":"Digest. Liver Dis."},{"key":"10.1016\/j.antiviral.2014.06.005_b0020","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.cgh.2013.03.032","article-title":"A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir","volume":"11","author":"Chen","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2014.06.005_b0025","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/hep.24636","article-title":"Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon\/ribavirin treatment in patients infected with hepatitis C virus genotype 1\/4","volume":"54","author":"D\u2019Avolio","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.06.005_b0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/FTD.0b013e31824bf778","article-title":"Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment","volume":"34","author":"D\u2019Avolio","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.antiviral.2014.06.005_b0035","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jhep.2013.04.038","article-title":"Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?","volume":"59","author":"D\u2019Avolio","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.06.005_b0040","doi-asserted-by":"crossref","unstructured":"D\u2019Avolio, A., De Nicolo, A., Agnesod, D., Simiele, M., Mohamed Abdi, A., Dilly Penchala, S., Boglione, L., Cariti, G., Di Perri, G., 2013b. A UPLC-MS\/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. J Pharm Biomed Anal 78-79, 217-223.","DOI":"10.1016\/j.jpba.2013.02.025"},{"key":"10.1016\/j.antiviral.2014.06.005_b0045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.antiviral.2013.07.021","article-title":"Association of ITPA polymorphisms rs6051702\/rs1127354 instead of rs7270101\/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients","volume":"100","author":"D\u2019Avolio","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.06.005_b0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jpba.2012.03.030","article-title":"Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients","volume":"66","author":"D\u2019Avolio","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.antiviral.2014.06.005_b0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2006.03.019","article-title":"Validation of liquid\/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients","volume":"835","author":"D\u2019Avolio","year":"2006","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.antiviral.2014.06.005_b0060","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage","volume":"31","author":"De Franceschi","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.06.005_b0065","first-page":"51","article-title":"P_21 Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population","volume":"3","author":"De Nicol\u00f2","year":"2013","journal-title":"Rev. Antiviral Ther. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.06.005_b0070","first-page":"21","article-title":"O_18 Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype","volume":"3","author":"De Nicol\u00f2","year":"2013","journal-title":"Rev. Antiviral Ther. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.06.005_b0075","doi-asserted-by":"crossref","unstructured":"Fukuda, K., Imai, Y., Hiramatsu, N., Irishio, K., Igura, T., Sawai, Y., Kogita, S., Makino, Y., Mizumoto, R., Matsumoto, Y., Nakahara, M., Zushi, S., Kajiwara, N., Oze, T., Kawata, S., Hayashi, N., Takehara, T., 2013. Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C. Hepatol Res.","DOI":"10.1111\/hepr.12229"},{"key":"10.1016\/j.antiviral.2014.06.005_b0080","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jac\/dkt371","article-title":"Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response","volume":"69","author":"Furusyo","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2014.06.005_b0085","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.06.005_b0090","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1097\/01.aids.0000247121.19951.fa","article-title":"Unexpected drug\u2013drug interaction between tipranavir\/ritonavir and enfuvirtide","volume":"20","author":"Gonzalez de Requena","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2014.06.005_b0095","first-page":"26","article-title":"PP_02 increased plasma and intracellular ribavirin concentrations associated with telaprevir use","volume":"3","author":"Hammond","year":"2013","journal-title":"Rev. Antiviral Ther. Infect. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2014.06.005_b0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1478-3231.2011.02707.x","article-title":"Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice","volume":"32","author":"Hezode","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2014.06.005_b0105","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.06.005_b0110","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.06.005_b0115","doi-asserted-by":"crossref","unstructured":"Karino, Y., Ozeki, I., Hige, S., Kimura, M., Arakawa, T., Nakajima, T., Kuwata, Y., Sato, T., Ohmura, T., Toyota, J., 2013. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir\/pegylated interferon\/ribavirin therapy for chronic hepatitis C. J Viral Hepat.","DOI":"10.1111\/jvh.12162"},{"key":"10.1016\/j.antiviral.2014.06.005_b0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clnu.2008.09.003","article-title":"Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alfa and ribavirin","volume":"28","author":"Lin","year":"2009","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.antiviral.2014.06.005_b0125","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.26602","article-title":"Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir","volume":"59","author":"Mauss","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2014.06.005_b0130","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1478-3231.2006.01228.x","article-title":"Definition and management of anemia in patients infected with hepatitis C virus","volume":"26","author":"McHutchison","year":"2006","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2014.06.005_b0135","doi-asserted-by":"crossref","unstructured":"Reesink, H.W., Zeuzem, S., Weegink, C.J., Forestier, N., van Vliet, A., van de Wetering de Rooij, J., McNair, L., Purdy, S., Kauffman, R., Alam, J., Jansen, P.L., 2006. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131, 997-1002.","DOI":"10.1053\/j.gastro.2006.07.013"},{"key":"10.1016\/j.antiviral.2014.06.005_b0140","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jhep.2013.07.014","article-title":"Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations","volume":"59","author":"Romero-Gomez","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.06.005_b0145","doi-asserted-by":"crossref","unstructured":"Ronzoni, L., Aghemo, A., Rumi, M.G., Prati, G., Colancecco, A., Porretti, L., Monico, S., Colombo, M., Cappellini, M.D., 2013. Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. J Viral Hepat.","DOI":"10.1111\/jvh.12158"},{"key":"10.1016\/j.antiviral.2014.06.005_b0150","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.06.005_b0155","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1093\/hmg\/ddr249","article-title":"Genome-wide association study identified ITPA\/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C","volume":"20","author":"Tanaka","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.antiviral.2014.06.005_b0160","doi-asserted-by":"crossref","unstructured":"Tempestilli, M., D\u2019Offizi, G., Lionetti, R., Montalbano, M., Giaffreda, A., Fazio, S., Pucillo, L.P., 2013. Increased plasma concentration of Ribavirin as a result of renal dysfunction in HCV patients treated with telaprevir. Hepatology.","DOI":"10.1002\/hep.26978"},{"key":"10.1016\/j.antiviral.2014.06.005_b0165","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2893.2012.01640.x","article-title":"Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b","volume":"20","author":"Toyota","year":"2013","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.antiviral.2014.06.005_b0170","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N. Engl. J. Med."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214001673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214001673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T15:43:06Z","timestamp":1565538186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214001673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":34,"alternative-id":["S0166354214001673"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.06.005","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}